2024
Brief Report: Differentiated Service Delivery Framework for People With Multidrug-Resistant Tuberculosis and HIV Coinfection
Reis K, Wolf A, Perumal R, Seepamore B, Guzman K, Ross J, Cheung Y, Amico K, Brust J, Padayatchi N, Friedland G, Naidoo K, Daftary A, Zelnick J, O'Donnell M. Brief Report: Differentiated Service Delivery Framework for People With Multidrug-Resistant Tuberculosis and HIV Coinfection. JAIDS Journal Of Acquired Immune Deficiency Syndromes 2024, 96: 34-39. PMID: 38323838, PMCID: PMC11300702, DOI: 10.1097/qai.0000000000003394.Peer-Reviewed Original ResearchMultidrug-resistant tuberculosisDifferentiated service deliveryAntiretroviral therapyElectronic dose monitoring devicesAntiretroviral therapy adherenceMultidrug-resistant tuberculosis treatmentDifferentiated service delivery modelsHIV co-infectionTreatment courseCumulative adherenceTreatment challengesCo-infectionBedaquilineTreatment completionFocus groupsMedication adherenceHIVTreatmentPatterns of medication adherenceAdherenceTuberculosisSubpopulationsHIV/AIDSTreatment stageStage-specific
2019
Impact of early antiretroviral treatment on sexual behaviour: a randomised comparison
Lampe FC, Rodger AJ, Burman W, Grulich A, Friedland G, Sadr WE, Neaton J, Corbelli GM, Emery S, Molina JM, Orkin C, Gatell J, Gerstoft J, Ruxrungtham K, de Souza M, Phillips AN. Impact of early antiretroviral treatment on sexual behaviour: a randomised comparison. AIDS 2019, 33: 2337-2350. PMID: 31764099, PMCID: PMC6882545, DOI: 10.1097/qad.0000000000002359.Peer-Reviewed Original ResearchConceptsEarly antiretroviral treatmentHIV-serodifferent partnersAntiretroviral treatmentMonth 12Month 24CD4 cell countHIV-positive adultsSexual behaviorHIV infectiousnessImmediate armViral suppressionPrimary outcomeHigh prevalenceCondomless sexCell countMSMCells/Lower absolute levelsSexHeterosexual menTreatmentHeterosexualsArmAbsolute levelsPrevalence
2014
Improved survival in multidrug-resistant tuberculosis patients receiving integrated tuberculosis and antiretroviral treatment in the SAPiT Trial
Padayatchi N, Abdool Karim SS, Naidoo K, Grobler A, Friedland G. Improved survival in multidrug-resistant tuberculosis patients receiving integrated tuberculosis and antiretroviral treatment in the SAPiT Trial. The International Journal Of Tuberculosis And Lung Disease 2014, 18: 147-154. PMID: 24429305, PMCID: PMC4770013, DOI: 10.5588/ijtld.13.0627.Peer-Reviewed Original ResearchConceptsMultidrug-resistant tuberculosisMDR-TB patientsSequential treatment armAnti-tuberculosis treatmentAntiretroviral treatmentTreatment armsFirst-line anti-tuberculosis treatmentMultidrug-resistant tuberculosis patientsHuman immunodeficiency virus (HIV) infectionImmunodeficiency virus infectionOut-patient clinicDrug susceptibility resultsSAPiT trialTuberculosis patientsClinical outcomesEarly initiationTherapeutic effectVirus infectionMortality ratePatientsTherapeutic outcomesSmall sample sizeTreatmentSusceptibility resultsTuberculosis
2010
The SAPIT trial provides essential evidence on risks and benefits of integrated and sequential treatment of HIV and tuberculosis
Karim Q, Karim S, Baxter C, Friedland G, Gengiah T, Gray A, Grobler A, Naidoo K, Padayatchi N, El-Sadr W. The SAPIT trial provides essential evidence on risks and benefits of integrated and sequential treatment of HIV and tuberculosis. South African Medical Journal 2010, 100: 808-809. PMID: 21414268, DOI: 10.7196/samj.4621.Peer-Reviewed Original Research
2009
Multidrug-resistant and extensively drug-resistant tuberculosis: consequences for the global HIV community
Shenoi S, Heysell S, Moll A, Friedland G. Multidrug-resistant and extensively drug-resistant tuberculosis: consequences for the global HIV community. Current Opinion In Infectious Diseases 2009, 22: 11-17. PMID: 19532076, PMCID: PMC3013226, DOI: 10.1097/qco.0b013e3283210020.Peer-Reviewed Original ResearchConceptsDrug-resistant tuberculosisHIV patientsHIV communityIntegration of tuberculosisIndependent risk factorCourse of treatmentCommunity-based treatmentHIV careNew rapid diagnosticsRisk factorsClinical careNegative individualsTuberculosisPatientsMultidrugRapid diagnosticsCareTreatmentSusceptibility informationMorbidityHIVInfectionMortalityPhysicians
2007
Managing multiple and extensively drug-resistant tuberculosis and HIV
Padayatchi N, Friedland G. Managing multiple and extensively drug-resistant tuberculosis and HIV. Expert Opinion On Pharmacotherapy 2007, 8: 1035-1037. PMID: 17516869, DOI: 10.1517/14656566.8.8.1035.Peer-Reviewed Original ResearchTuberculosis, drug resistance, and HIV/AIDS: A triple threat
Friedland G. Tuberculosis, drug resistance, and HIV/AIDS: A triple threat. Current Infectious Disease Reports 2007, 9: 252. PMID: 17430708, DOI: 10.1007/s11908-007-0039-7.Peer-Reviewed Original ResearchTB drug resistanceHIV/AIDSDrug-resistant tuberculosisDrug resistanceTB control programsRapid molecular diagnostic techniquesMultiple drug resistanceAvailable diagnostic technologiesMolecular diagnostic techniquesTB diagnosisWorldwide epidemicTreatment successTherapeutic strategiesTuberculosisTherapeutic agentsAIDSThird epidemicTreatmentDiagnosisDiagnostic techniquesControl programsDiagnostic technologiesEpidemicTriple threatUrgent need
2006
Opioid Dependence: Rationale for and Efficacy of Existing and New Treatments
Fiellin DA, Friedland GH, Gourevitch MN. Opioid Dependence: Rationale for and Efficacy of Existing and New Treatments. Clinical Infectious Diseases 2006, 43: s173-s177. PMID: 17109303, DOI: 10.1086/508180.BooksConceptsOpioid agonist treatmentOpioid dependenceAgonist treatmentHuman immunodeficiency virus (HIV) transmissionBuprenorphine/naloxone combinationNeurobiological basisOpioid withdrawalBuprenorphine treatmentHIV infectionDecreased riskNaloxone combinationOpioid receptorsGeneral physiciansMedical disordersNew treatmentsMethadoneVirus transmissionBuprenorphineTreatmentMedicationsPatientsChronicInfectionIntracellular processesPhysicians
2003
The Protease Inhibitor Lopinavir-Ritonavir May Produce Opiate Withdrawal in Methadone-Maintained Patients
McCance-Katz EF, Rainey PM, Friedland G, Jatlow P. The Protease Inhibitor Lopinavir-Ritonavir May Produce Opiate Withdrawal in Methadone-Maintained Patients. Clinical Infectious Diseases 2003, 37: 476-482. PMID: 12905130, DOI: 10.1086/376907.Peer-Reviewed Original ResearchConceptsLopinavir-ritonavirMethadone metabolismSubstance abuse pharmacotherapyOpiate withdrawal symptomsInjection drug usersConcentration-time curveMethadone areaMethadone dosesHIV diseaseMethadone concentrationsOral clearancePharmacodynamic interactionsWithdrawal symptomsOpiate withdrawalClinical monitoringDrug usersSame dosageRitonavirPotent inducerPatientsMethadoneProtease inhibitorsSignificant reductionR formulationTreatment
2002
Increasing drug users’ adherence to HIV treatment: results of a peer-driven intervention feasibility study
Broadhead RS, Heckathorn DD, Altice FL, van Hulst Y, Carbone M, Friedland GH, O’Connor P, Selwyn PA. Increasing drug users’ adherence to HIV treatment: results of a peer-driven intervention feasibility study. Social Science & Medicine 2002, 55: 235-246. PMID: 12144138, DOI: 10.1016/s0277-9536(01)00167-8.Peer-Reviewed Original ResearchConceptsActive drug usersDrug users' adherenceDrug usersDrug treatmentMedical carePrimary careIntervention feasibility studySocial support structuresHealth advocatesUser adherenceTreatment program staffPeer-driven interventionHIV diseaseHIV infectionPatient adherenceSix-month studyHIV treatmentPhysician referralClinical appointmentsHIV therapeuticsCarePositive behavioral changesAdherencePeer pressureTreatment
1999
Tuberculosis and HIV infection
Buitrago M, Friedland G. Tuberculosis and HIV infection. Current Infectious Disease Reports 1999, 1: 105-109. PMID: 11095774, DOI: 10.1007/s11908-999-0017-3.ChaptersProphylaxis of tuberculosisExpert consensus panelAntituberculous regimensAntiretroviral medicationsHIV infectionImportant new recommendationsEquivalent efficacyDrug interactionsConsensus panelShort courseLarge-scale studiesTuberculosisProphylaxisRegimensRifampinTreatmentNew recommendationsMedicationsHIVRifabutinInfectionIndividuals
1995
Heroin use during methadone maintenance treatment: the importance of methadone dose and cocaine use.
Hartel D, Schoenbaum E, Selwyn P, Kline J, Davenny K, Klein R, Friedland G. Heroin use during methadone maintenance treatment: the importance of methadone dose and cocaine use. American Journal Of Public Health 1995, 85: 83-88. PMID: 7832267, PMCID: PMC1615273, DOI: 10.2105/ajph.85.1.83.Peer-Reviewed Original ResearchConceptsMethadone maintenance treatmentHeroin useMaintenance treatmentHigh-dose methadone maintenanceCocaine useMethadone dosage levelsNonusers of cocaineMethadone doseLogistic regression statistical modelMethadone dosageMethadone patientsTreatment complianceMethadone maintenanceIndependent associationTreatment durationCross-sectional samplePatientsAlcohol useDosage levelsCocaine usersSocioeconomic factorsTreatmentFurther investigationCocaineNonusers